Device/Diagnostics Quarterly Deal Statistics, Q4 2015
Executive Summary
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
You may also be interested in...
Mega Medtech M&A Momentum In 2015
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.
Biopharma Quarterly Dealmaking Statistics, Q1 2020
During Q1, biopharmas brought in an aggregate $13.8bn in financing. M&A value reached $6.9bn, the majority from Gilead Sciences $4.9bn purchase of immuno-oncology firm Forty Seven. Alliances fetched $35bn in potential deal value, dominated by many Big Pharma tie-ups led by a $4bn discovery and development collaboration between AstraZeneca and Silence Therapeutics for siRNA therapeutics.
Deals In Depth: March And April 2020
AstraZeneca and Silence Therapeutics entered a March alliance worth up to $4.08bn for the discovery and development of siRNA drugs for cardiovascular, renal, metabolic and respiratory diseases, while the top April deal was a $3.9bn tie up between Fate Therapeutics and Janssen for iPSC-derived cell-based cancer immunotherapies.
Need a specific report? 1000+ reports available
Buy Reports